is there still a glp-1 shortage FDA's compounded limits will have ripple effects throughout the retail industry FDA's GLP-1 decision kicks off

If the program transitions into a full marketplace offering in 2028, it would mark one of the most significant Medicare expansions of prescription drug coverage in years, particularly for obesity treatment, which affects a large share of older Americans

Our team provides education, evaluation, and personalized weight loss planning so patients can make informed decisions about available and appropriate treatment options

We are committed to providing our patients with the most advanced options for supporting healthy weight loss

How do GLP-1 drugs lead to weight loss

One targets hormonal satiety signals while the other suppresses the central nervous systems hunger response

Here is what to expect post-approval: | Insurance Type | Expected Coverage | Timeline | |---------------|-------------------|----------| | Employer-sponsored (large) | Likely with prior auth | 6-12 months post-approval | | Employer-sponsored (small) | Variable | 12-24 months post-approval | | Medicare Part D | Possible after CMS review | 12-18 months post-approval | | Medicaid | State-dependent | 18-36 months post-approval | | ACA Marketplace | Varies by plan | 12-24 months post-approval | **Key factor:** The Treat and Reduce Obesity Act and evolving anti-obesity medication (AOM) coverage policies may accelerate insurance adoption